FDA Approves Teva’s Weltruza, a Monthly Shot With No Observation Window

FDA approved Weltruza — Teva's brand name for olanzapine extended-release injectable suspension — on 9 October 2026 for adults with schizophrenia. It is the first once-monthly subcutaneous formulation of olanzapine to reach the U.S. market, and the detail that will draw the most attention from prescribers and risk-management staff alike is what is missing from the label: no loading dose, no oral supplementation during the switch, and no mandated post-injection observation period.

What the REMS comparison actually turns on

Long-acting injectable antipsychotics solve an adherence problem — patients who stop taking a daily pill relapse at much higher rates than patients on a monthly depot — but olanzapine's only prior depot formulation came with a real safety tradeoff. Zyprexa Relprevv is absorbed intramuscularly in a way that can, in a small fraction of injections, release a large bolus of drug into the bloodstream quickly enough to cause post-injection delirium/sedation syndrome: dizziness, confusion, and in the most severe reported cases, sedation deep enough to require hospitalization. FDA's response when it approved Relprevv in 2009 was a REMS strict enough that it shaped how the drug is used in practice — every injection happens in a certified facility, under direct observation, for at least three hours, with the prescriber, the site, the patient and the dispensing pharmacy all separately enrolled.

Weltruza's subcutaneous route is the mechanistic reason FDA did not require the same safeguard: delivered under the skin rather than into muscle, the SteadyTeq depot is designed to avoid the rapid-absorption spikes that drive PDSS risk with the intramuscular formulation. Teva and Medincell's submission leaned on that mechanism along with a clean safety record in SOLARIS. For a regulatory affairs team, the approval is a useful data point on how literally FDA will read a delivery-route distinction when deciding whether a REMS is “necessary to ensure the benefits of the drug outweigh its risks” under the agency's REMS authority — here, a different injection site, not a new molecule, was enough to change that calculus for an entire antipsychotic subclass.

What the trial showed

SOLARIS is Weltruza's pivotal Phase 3 program, run in adult patients with schizophrenia. In the placebo-controlled acute phase, the drug met its primary endpoint — a statistically significant improvement over placebo on the Positive and Negative Syndrome Scale (PANSS) total score by week 8 — and showed secondary improvement on the Clinical Global Impression-Severity (CGI-S) scale and the Personal and Social Performance (PSP) scale, which Teva has highlighted as evidence the drug moves beyond symptom control into functional improvement. Across the acute and long-term safety data Teva and Medincell have presented at psychiatric conferences since 2024, the companies report no confirmed or suspected PDSS events among SOLARIS participants on the subcutaneous formulation, including through extended follow-up. That safety record, not a head-to-head trial against Relprevv, is the evidentiary basis for the REMS-free label; FDA's own trial data and risk assessment, not reflected in SOLARIS topline results alone, ultimately govern the labeling decision.

What it means for RA/QA teams

For sponsors developing their own long-acting injectables, Weltruza is a live precedent that a delivery-route change can be the basis for dropping a REMS carried by an earlier formulation in the same drug class — provided the safety case for why the new route avoids the original risk is built into the clinical program from the start, not retrofitted after a REMS is already in place. For pharmacy and site-of-care operations, a REMS-free monthly olanzapine removes the facility-certification and monitored-observation logistics that have made Relprevv a harder product to stock and administer outside specialized behavioral-health settings, which is likely to be central to how Teva positions Weltruza against both oral olanzapine and other long-acting antipsychotics once it launches in the coming weeks. Full prescribing information, including any boxed warnings retained from the olanzapine class label, becomes the reference document as it posts to Drugs@FDA.

Frequently asked questions

What did FDA approve on 9 October 2026?

Weltruza, Teva's brand name for olanzapine extended-release injectable suspension, in three once-monthly subcutaneous strengths — 318 mg, 425 mg and 531 mg — corresponding to the approved oral olanzapine doses of 10 mg, 15 mg and 20 mg, indicated for adults with schizophrenia.

Why does skipping the observation window matter?

The only other long-acting injectable olanzapine on the U.S. market, Eli Lilly's intramuscular Zyprexa Relprevv, carries a REMS requiring at least three hours of in-clinic observation after every injection because of a small risk of post-injection delirium/sedation syndrome. Weltruza's label carries no such requirement.

What is the evidence behind the no-monitoring decision?

Teva and Medincell report zero confirmed or suspected post-injection delirium/sedation syndrome events among SOLARIS trial participants on the subcutaneous formulation, including in long-term follow-up. The Phase 3 trial also met its primary endpoint on the PANSS total symptom score against placebo at week 8.

What technology enables the subcutaneous route?

Weltruza uses Medincell's SteadyTeq (BEPO) copolymer depot platform, a biodegradable gel delivered under the skin that releases drug over roughly a month — the platform's second FDA approval, after Teva's risperidone product Uzedy in April 2023.